

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 12,500 条结果 (用时 0.43 秒)

(PDF) Ipilimumab and Nivolumab induced steroid-refractory colitis ...

https://www.researchgate.net/.../330522809_Ipilimumab_and_Nivolumab_in... - 翻译此页

2019年1月25日 - ... steroid-refractory colitis treated with infliximab: A case report. ... and colitis in patients with advanced malignancies: Retrospective review at MD Anderson ... Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis ... antiprogrammed death receptor-1 or a combination of both.

(PDF) Vedolizumab and Infliximab Combination Therapy in the ...

https://www.researchgate.net/.../287213505_Vedolizumab_and_Infliximab_... - 翻译此页

2018年6月6日 - In 2 case reports previously published vedolizumab was ... to infliximab therapy has been described in refractory cases [8, 9]. ... A Challenging Case of Severe Ulcerative Colitis following the Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. Article.

(PDF) Resolution of Infliximab-Refractory Nivolumab-Induced Acute ...

https://www.researchgate.net/.../324042117_Resolution_of_Infliximab-Refra... - 翻译此页

2019年1月13日 - Article (PDF Available) in American Journal of Case Reports Induced Acute Severe Enterocolitis After ... Background: Enterocolitis is an immune-related adverse event ... cases in the literature is scarce, although the use of tacrolim- Vedolizumab treatment for immune checkpoint inhibitor-induced ...

Emerging Role of Vedolizumab in Managing Refractory Immune ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830540/> - 翻译此页

作者: P Diana - 2018 - 被引用次数: 4 - 相关文章

2018年2月28日 - Her diarrhea quickly resolved after infusion of vedolizumab, and the ... can trigger various organ-specific immune-related adverse events, ... We describe a case of severe ICI-induced enteritis secondary to combination ... Second, in patients refractory to a first or second dose of infliximab, the See reviews.

缺少字词: literature

1

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 46789

Manuscript Type: CASE REPORT

Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report

Randhawa M *et al.* Vedolizumab in immune-related colitis

Manreet Randhawa, Gregory Gaughran, Christine Archer, Paul Pavli, Sayed Ali, Desmond Yip

Abstract

BACKGROUND

Dual checkpoint inhibition improves response rates in treatment naïve patients with metastatic melanoma compared to monotherapy. However, it confers a higher rate of toxicity, including immune-related colitis. Steroids may not resolve symptoms in all cases. The use of vedolizumab, a humanized monoclonal antibody against $\alpha 4\beta 7$ integrin has proven effective in cases refractory to standard treatment.

CASE SUMMARY

We report the case of a 27-year-old female with Stage IVd metastatic melanoma treated with ipilimumab and nivolumab. She developed severe colitis refractory to

Match Overview

1	Internet 32 words crawled on 10-Dec-2014 www.ncbi.nlm.nih.gov	1%
2	Internet 25 words crawled on 30-Mar-2019 jitc.biomedcentral.com	1%
3	Internet 17 words crawled on 02-Mar-2019 biomedigs.org	1%
4	Internet 14 words crawled on 12-May-2016 documents.mx	1%
5	Internet 13 words crawled on 30-Jun-2019 link.springer.com	<1%
6	Internet 13 words crawled on 08-Jun-2019 www.karger.com	<1%
7	Internet 13 words crawled on 07-Apr-2019 academic.oup.com	<1%
8	Crossref 12 words "Clinical Vignettes/Case Reports - Esophagus", The American Journal of Gastroenterology, 2013	<1%



国内版

国际版

Vedolizumab in combined immune checkpoint therapy-induced infliximab-refract



All

Images

Videos

翻译成中文

关闭取词

12,300 Results

Any time ▾

Vedolizumab treatment for immune checkpoint inhibitor ...

<https://link.springer.com/article/10.1007/s00262-017-1962-6> ▾

Vedolizumab is an anti-integrin $\alpha 4\beta 7$ antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and **ulcerative colitis**. We report a case series of seven patients with **metastatic melanoma** or **lung cancer**, treated with **vedolizumab** off-label for **ipilimumab**- or **nivolumab**-induced **enterocolitis**, from June 2014 through October 2016.

Cited by: 63

Author: Viktoria Bergqvist, Erik Hertvig, Peter G...

Publish Year: 2017

Outcomes of vedolizumab therapy in patients with immune ...

<https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0461-4> ▾

Dec 05, 2018 · **Immune**-mediated diarrhea and **colitis** (IMDC) can limit **immune checkpoint** inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids and infliximab are commonly used to treat it. These agents induce systemic immunosuppression, with its associated morbidity. We assessed clinical outcomes of **vedolizumab** as an alternative treatment for IMDC.

Cited by: 6

Author: Hamzah Abu-Sbeih, Faisal S. Ali, Dana ...

Publish Year: 2018

Vedolizumab treatment for immune checkpoint inhibitor ...

<https://www.ncbi.nlm.nih.gov/pubmed/28204866>

Vedolizumab is an anti-integrin $\alpha 4\beta 7$ antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and ulcerative **colitis**. We **report a case** series of seven patients **with metastatic melanoma** or lung cancer, treated with **vedolizumab** off-label for ipilimumab- or nivolumab-induced enterocolitis, from June 2014 through October ...

Cited by: 63

Author: Viktoria Bergqvist, Erik Hertvig, Peter G...

Publish Year: 2017

Resumption of Immune Checkpoint Inhibitor Therapy After ...

<https://ascopubs.org/doi/full/10.1200/JCO.19.00320>

Jun 04, 2019 · **Immune checkpoint** inhibitor (ICI) therapy often is suspended because of **immune**-mediated diarrhea and **colitis** (IMDC). We examined the rate of and risk factors for IMDC recurrence after ICI resumption. This retrospective multicenter study examined patients who resumed ICI therapy after improvement of ...

Author: Hamzah Abu-Sbeih, Faisal S. Ali, Ab...

Publish Year: 2019



国内版

国际版

Vedolizumab in combined immune checkpoint therapy-induced infliximab-refract



All

Images

Videos

翻译成中文

开启取词

12,300 Results

Any time ▾

Vedolizumab treatment for immune checkpoint inhibitor ...

<https://link.springer.com/article/10.1007/s00262-017-1962-6> ▾

Vedolizumab is an anti-integrin $\alpha 4\beta 7$ antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and ulcerative colitis. We report a case series of seven patients with metastatic melanoma or lung cancer, treated with vedolizumab off-label for ipilimumab- or nivolumab-induced enterocolitis, from June 2014 through October 2016.

Cited by: 63

Author: Viktoria Bergqvist, Erik Hertervig, Peter G...

Publish Year: 2017

Outcomes of vedolizumab therapy in patients with immune ...

<https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0461-4> ▾

Dec 05, 2018 · Immune-mediated diarrhea and colitis (IMDC) can limit immune checkpoint inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids and infliximab are commonly used to treat it. These agents induce systemic immunosuppression, with its associated morbidity. We assessed clinical outcomes of vedolizumab as an alternative treatment for IMDC.

Cited by: 6

Author: Hamzah Abu-Sbeih, Faisal S. Ali, Dana Al...

Publish Year: 2018

Vedolizumab treatment for immune checkpoint inhibitor ...

<https://www.ncbi.nlm.nih.gov/pubmed/28204866>

Vedolizumab is an anti-integrin $\alpha 4\beta 7$ antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and ulcerative colitis. We report a case series of seven patients with metastatic melanoma or lung cancer, treated with vedolizumab off-label for ipilimumab- or nivolumab-induced enterocolitis, from June 2014 through October ...

Cited by: 63

Author: Viktoria Bergqvist, Erik Hertervig, Peter G...

Publish Year: 2017

Severe immune mucositis and esophagitis in metastatic ...

<https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0332-z> ▾

Mar 16, 2018 · The patient did not develop other immune related toxicity to pembrolizumab. After 14 cycles, complete metastatic disease regression was documented in the right inferior pulmonary lobe, hilar, anterior mediastinal and pretracheal lymph nodes and in the right upper lobe micronodules and a left pulmonary micronodule was stable.

Cited by: 3

Author: Fanny Zulay Acero Brand, Nicolas Suter, ...

Publish Year: 2018

Vedolizumab treatment for immune checkpoint inhibitor ...

<https://paperity.org/p/78939863/vedolizumab-treatment-for-immune-checkpoint-inhibitor...> ▾

Vedolizumab is an anti-integrin $\alpha 4\beta 7$ antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and ulcerative colitis. We report a case series of seven patients with metastatic melanoma or lung cancer, treated with vedolizumab off-label for ipilimumab- or nivolumab-induced